Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ILT4.4-1BB.DAP10 CIR-NK
- Development stage
- Preclinical
- Lead developer
- NKILT Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ILT4.4-1BB.DAP10 CIR-NK is an engineered Natural Killer (NK) cell therapy developed by NKILT Therapeutics. It utilizes a Chimeric ILT Receptor (CIR) consisting of the extracellular domain of the Immunoglobulin-Like Transcript 4 (ILT4) receptor fused to intracellular costimulatory domains from 4-1BB and DAP10. This construct is designed to target tumor cells expressing Human Leukocyte Antigen G (HLA-G), an immune checkpoint often upregulated in cancers to evade immune surveillance. By binding HLA-G, the CIR-NK cells trigger activation and tumor cell lysis rather than the typical immunosuppression associated with HLA-G/ILT4 interaction. The cells are also engineered to express soluble IL-15 to enhance persistence and expansion.
- Other names
- ILT4.4-1BB.DAP10 CIR-NK cellsILT-4.4-1BB.DAP10 CIR-NK cellsILT 4.4-1BB.DAP10 CIR-NK cellsILT4.4-1BB.DAP10 CIR™NK
02
Targets
HLA-G (Human leukocyte antigen G)
Beyond the preview
Go deeper on ILT4.4-1BB.DAP10 CIR-NK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ILT4.4-1BB.DAP10 CIR-NK.